Freeline Therapeutics Holdings plc
NASDAQ:FRLN
6.49 (USD) • At close February 16, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q2 | 2019 Q1 | 2018 Q2 | 2018 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.005 | 0.617 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.384 | 0.434 | 0.323 | 0.317 | 0.403 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.379 | 0.183 | -0.323 | -0.317 | -0.403 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| -75.752 | 0.296 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 5.788 | 8.827 | 10.893 | 12.642 | 14.776 | 18.837 | 19.948 | 24.604 | 22.695 | 24.269 | 23.863 | 20.882 | 25.822 | 11.988 | 17.457 | 11.761 | 11.761 | 8.548 | 8.548 |
| General & Administrative Expenses
| 6.4 | 9.496 | 8.052 | 5.645 | 8.732 | 8.055 | 8.223 | 7.349 | 12.604 | 14.537 | 10.078 | 11.377 | 3.26 | 7.929 | 3.734 | 4.15 | 4.15 | 1.698 | 1.698 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 6.4 | 9.496 | 8.052 | 5.645 | 8.732 | 8.055 | 8.223 | 7.349 | 12.604 | 14.537 | 10.078 | 11.377 | 3.26 | 7.929 | 3.734 | 4.15 | 4.15 | 1.698 | 1.698 |
| Other Expenses
| -0.034 | -0.591 | -0.261 | -0.267 | -0.583 | -0.335 | -0.386 | -0.658 | 3.86 | -1.634 | -1.733 | -10.036 | -0.114 | -0.001 | 0.863 | -31.822 | -31.822 | -20.491 | -20.491 |
| Operating Expenses
| 12.033 | 18.12 | 18.684 | 18.02 | 22.925 | 26.557 | 27.785 | 31.403 | 34.808 | 38.354 | 33.343 | 28.117 | 24.849 | 16.725 | 17.489 | -15.911 | -15.911 | -10.245 | -10.245 |
| Operating Income
| -12.266 | -15.651 | -20.082 | -19.877 | -23.507 | -26.892 | -28.171 | -34.333 | -35.299 | -38.806 | -33.941 | -32.259 | -29.082 | -19.916 | -21.192 | -15.911 | -15.911 | -10.245 | -10.245 |
| Operating Income Ratio
| -2,453.2 | -25.366 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -0.117 | 1.464 | 21.41 | -2.85 | 8.664 | 2.569 | 1.46 | -3.039 | 3.86 | -1.634 | -1.733 | -10.036 | -0.114 | -0.001 | 0.863 | 2.469 | 2.469 | 1.931 | 1.931 |
| Income Before Tax
| -12.047 | -16.005 | 1.328 | -22.727 | -14.843 | -24.323 | -26.711 | -34.387 | -30.863 | -39.863 | -34.936 | -38.022 | -24.907 | -16.69 | -16.574 | -13.442 | -13.442 | -8.314 | -8.314 |
| Income Before Tax Ratio
| -2,409.4 | -25.94 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.041 | 0.006 | 0.162 | 0.272 | 0.05 | 0.024 | 0.022 | 0.313 | 0.013 | 0.007 | 0.009 | 0.055 | 0.074 | -0.131 | 0.131 | 0.035 | 0.035 | 0.007 | 0.007 |
| Net Income
| -12.088 | -16.011 | 1.166 | -22.999 | -14.893 | -24.347 | -26.733 | -34.7 | -30.876 | -39.87 | -34.945 | -38.077 | -24.981 | -16.559 | -16.705 | -13.477 | -13.477 | -8.321 | -8.321 |
| Net Income Ratio
| -2,417.6 | -25.95 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.77 | -3.69 | 0.3 | -5.31 | -3.44 | -5.66 | -9.4 | -14.56 | -12.96 | -16.76 | -14.7 | -15.93 | -10.78 | -7.24 | -39.47 | -0.63 | -0.63 | -0.39 | -0.39 |
| EPS Diluted
| -2.77 | -3.69 | 0.3 | -5.31 | -3.44 | -5.66 | -9.4 | -14.56 | -12.96 | -16.76 | -14.7 | -15.93 | -10.78 | -7.24 | -39.47 | -0.63 | -0.63 | -0.39 | -0.39 |
| EBITDA
| -11.559 | -19.125 | -37.506 | -16.026 | -22.519 | -26.078 | -27.244 | -30.792 | -34.22 | -37.736 | -32.77 | -27.532 | -24.383 | -16.358 | -16.994 | -13.057 | -13.057 | -8.072 | -8.072 |
| EBITDA Ratio
| -2,311.8 | -30.997 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |